THORAC-话题@MedSci

#THORAC#

175篇内容 | 3590人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2057108, encodeId=77a7205e1087f, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=Interact Cardiovasc Thorac Surg：阜外医院郑哲发现房颤伴左房扩大，外科微创消融双房更有效！, objectType=article, longId=301185, objectId=4300301185c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4300301185c1, replyNumber=0, likeNumber=91, createdTime=2022-07-16, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4300301185c1, moduleTitle=Interact Cardiovasc Thorac Surg：阜外医院郑哲发现房颤伴左房扩大，外科微创消融双房更有效！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4300301185c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057103, encodeId=c852205e10343, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=J Thorac Oncol：Lorlatinib（劳拉替尼）治疗ALK+ NSCLC患者进展后继续使用仍然有效, objectType=article, longId=294238, objectId=ea07294238cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea07294238cf, replyNumber=0, likeNumber=58, createdTime=2022-02-25, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea07294238cf, moduleTitle=J Thorac Oncol：Lorlatinib（劳拉替尼）治疗ALK+ NSCLC患者进展后继续使用仍然有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea07294238cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057097, encodeId=ed0a205e0970f, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=Thorac Cancer：术后放疗可提高新辅助化疗+术后病理为ypN2的非小细胞肺癌患者的生存：来自SEER数据库倾向评分匹配分析, objectType=article, longId=291956, objectId=2f9f2919568c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f9f2919568c, replyNumber=0, likeNumber=57, createdTime=2021-12-25, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f9f2919568c, moduleTitle=Thorac Cancer：术后放疗可提高新辅助化疗+术后病理为ypN2的非小细胞肺癌患者的生存：来自SEER数据库倾向评分匹配分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f9f2919568c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057118, encodeId=bdbb205e1182d, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=Thorac Cancer：多中心回顾性研究评估dacomitinib（达可替尼）再挑战EGFR突变NSCLC患者的疗效, objectType=article, longId=727665, objectId=42bae2766592, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=42bae2766592, replyNumber=0, likeNumber=69, createdTime=2023-03-18, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=42bae2766592, moduleTitle=Thorac Cancer：多中心回顾性研究评估dacomitinib（达可替尼）再挑战EGFR突变NSCLC患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=42bae2766592)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057120, encodeId=bbbe205e12000, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=Thorac Cancer：真实世界中晚期NSCLC患者伴有KRAS、MET、FGFR、RET、BRAF和HER2改变时一线使用免疫检查点抑制剂(ICIs)的疗效, objectType=article, longId=727690, objectId=5f10e2769003, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f10e2769003, replyNumber=0, likeNumber=65, createdTime=2023-01-03, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f10e2769003, moduleTitle=Thorac Cancer：真实世界中晚期NSCLC患者伴有KRAS、MET、FGFR、RET、BRAF和HER2改变时一线使用免疫检查点抑制剂(ICIs)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f10e2769003)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057096, encodeId=73e7205e09603, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=Thorac Cancer：伴有罕见突变的晚期或转移性NSCLC患者的真实世界数据, objectType=article, longId=264988, objectId=11502649888a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11502649888a, replyNumber=0, likeNumber=75, createdTime=2022-10-14, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11502649888a, moduleTitle=Thorac Cancer：伴有罕见突变的晚期或转移性NSCLC患者的真实世界数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11502649888a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057084, encodeId=6cf3205e084ce, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=J Thorac Oncol：纳武单抗+伊匹单抗治疗晚期非小细胞肺癌的长期疗效, objectType=article, longId=218857, objectId=7f8121885e24, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f8121885e24, replyNumber=0, likeNumber=78, createdTime=2022-06-26, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f8121885e24, moduleTitle=J Thorac Oncol：纳武单抗+伊匹单抗治疗晚期非小细胞肺癌的长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f8121885e24)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057119, encodeId=91f4205e119d6, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=Thorac Cancer:淋巴结阳性(cN+)和阴性(cN0)的I期NSCLC患者术后无病生存(DFS)差异, objectType=article, longId=727693, objectId=a4d6e2769330, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a4d6e2769330, replyNumber=0, likeNumber=66, createdTime=2023-03-20, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a4d6e2769330, moduleTitle=Thorac Cancer:淋巴结阳性(cN+)和阴性(cN0)的I期NSCLC患者术后无病生存(DFS)差异, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a4d6e2769330)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057099, encodeId=98f6205e09976, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=Thorac Cancer：晚期NSCLC奥希替尼治疗进展后化疗联合免疫治疗优于单纯化疗, objectType=article, longId=293503, objectId=164d293503c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=164d293503c3, replyNumber=0, likeNumber=69, createdTime=2022-01-21, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=164d293503c3, moduleTitle=Thorac Cancer：晚期NSCLC奥希替尼治疗进展后化疗联合免疫治疗优于单纯化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=164d293503c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057106, encodeId=ed3b205e10676, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=Thorac Cancer：ALK阳性是I期完全切除的肺腺癌患者无复发生存期（RFS）负性预测指标, objectType=article, longId=300924, objectId=c0743009248b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0743009248b, replyNumber=0, likeNumber=126, createdTime=2022-12-21, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0743009248b, moduleTitle=Thorac Cancer：ALK阳性是I期完全切除的肺腺癌患者无复发生存期（RFS）负性预测指标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0743009248b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057090, encodeId=bb4b205e090a5, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=Thorac Cancer： EGFR-TKIs提前应用可改善不可切除的III期EGFR突变肺腺癌的预后, objectType=article, longId=220997, objectId=b57822099e0a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b57822099e0a, replyNumber=0, likeNumber=79, createdTime=2022-08-22, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b57822099e0a, moduleTitle=Thorac Cancer： EGFR-TKIs提前应用可改善不可切除的III期EGFR突变肺腺癌的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b57822099e0a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057071, encodeId=5e57205e071d6, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=J Thorac Oncol: 替雷利珠单抗（Tislelizumab）联合化疗一线治疗局部进展或转移性非鳞状非小细胞肺癌（nsq-NSCLC）的疗效和安全性(RATIONALE 304): 3期临床研究, objectType=article, longId=213120, objectId=686b21312019, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=686b21312019, replyNumber=0, likeNumber=71, createdTime=2021-06-23, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=686b21312019, moduleTitle=J Thorac Oncol: 替雷利珠单抗（Tislelizumab）联合化疗一线治疗局部进展或转移性非鳞状非小细胞肺癌（nsq-NSCLC）的疗效和安全性(RATIONALE 304): 3期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=686b21312019)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057091, encodeId=b2f8205e09170, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=Thorac Cancer：伴有EGFR-T790M突变的NSCLC患者，后续奥希替尼不同顺序治疗生存对比, objectType=article, longId=220998, objectId=36ac220998de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36ac220998de, replyNumber=0, likeNumber=66, createdTime=2022-01-31, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36ac220998de, moduleTitle=Thorac Cancer：伴有EGFR-T790M突变的NSCLC患者，后续奥希替尼不同顺序治疗生存对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36ac220998de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057107, encodeId=701b205e10746, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=J Thorac Oncol：新冠肺炎诊断的胸部恶性肿瘤患者的明确预测系统, objectType=article, longId=300746, objectId=86ee300e461a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=86ee300e461a, replyNumber=0, likeNumber=69, createdTime=2022-12-07, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=86ee300e461a, moduleTitle=J Thorac Oncol：新冠肺炎诊断的胸部恶性肿瘤患者的明确预测系统, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=86ee300e461a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057073, encodeId=bfa8205e07339, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=J Thorac Oncol: 真实世界中III期非小细胞肺癌（NSCLC）的治疗模式和临床预后：KINDLE国际多中心回顾性研究, objectType=article, longId=213198, objectId=1fee213198a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1fee213198a9, replyNumber=0, likeNumber=111, createdTime=2021-11-10, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1fee213198a9, moduleTitle=J Thorac Oncol: 真实世界中III期非小细胞肺癌（NSCLC）的治疗模式和临床预后：KINDLE国际多中心回顾性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1fee213198a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057069, encodeId=5fa5205e06913, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=J Thorac Oncol：针对原发性肺癌的低剂量CT（LDCT）筛查对后续发生脑转移（BM）风险的影响。, objectType=article, longId=212257, objectId=dfb621225edc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfb621225edc, replyNumber=0, likeNumber=78, createdTime=2021-12-23, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfb621225edc, moduleTitle=J Thorac Oncol：针对原发性肺癌的低剂量CT（LDCT）筛查对后续发生脑转移（BM）风险的影响。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dfb621225edc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057066, encodeId=debc205e06660, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=J Thorac Oncol：德瓦鲁单抗（durvalumab）维持治疗在EGFR和HER2突变不可切除III期NSCLC患者的作用, objectType=article, longId=211341, objectId=0e6621134127, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e6621134127, replyNumber=0, likeNumber=64, createdTime=2021-08-06, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e6621134127, moduleTitle=J Thorac Oncol：德瓦鲁单抗（durvalumab）维持治疗在EGFR和HER2突变不可切除III期NSCLC患者的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e6621134127)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057061, encodeId=72e1205e06148, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=J Thorac Oncol：布里加替尼治疗晚期ALK+NSCLC患者的初步结果, objectType=article, longId=210605, objectId=efad2106052b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=efad2106052b, replyNumber=0, likeNumber=68, createdTime=2022-02-14, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=efad2106052b, moduleTitle=J Thorac Oncol：布里加替尼治疗晚期ALK+NSCLC患者的初步结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=efad2106052b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057081, encodeId=803f205e081cf, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=J Thorac Oncol：Brigatinib（布加替尼）vs Crizotinib（克唑替尼）治疗未治ALK阳性晚期非小细胞肺癌患者的疗效：3期临床研究ALTA-1L最终分析结果, objectType=article, longId=217316, objectId=e44421e31653, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e44421e31653, replyNumber=0, likeNumber=63, createdTime=2022-06-14, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e44421e31653, moduleTitle=J Thorac Oncol：Brigatinib（布加替尼）vs Crizotinib（克唑替尼）治疗未治ALK阳性晚期非小细胞肺癌患者的疗效：3期临床研究ALTA-1L最终分析结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e44421e31653)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057086, encodeId=7da0205e0869e, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=J Thorac Oncol：Durvalumab +tremelimumab联合或不联合化疗一线治疗驱动基因阴性的转移性NSCLC患者的疗效和安全性, objectType=article, longId=220795, objectId=abf7220e9596, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=abf7220e9596, replyNumber=0, likeNumber=57, createdTime=2022-05-08, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=abf7220e9596, moduleTitle=J Thorac Oncol：Durvalumab +tremelimumab联合或不联合化疗一线治疗驱动基因阴性的转移性NSCLC患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=abf7220e9596)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

THORAC

2020-05-29

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

Interact Cardiovasc Thorac Surg：阜外医院郑哲发现房颤伴左房扩大，外科微创消融双房更有效！

2022-07-16

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

J Thorac Oncol：Lorlatinib（劳拉替尼）治疗ALK+ NSCLC患者进展后继续使用仍然有效

2022-02-25

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

Thorac Cancer：术后放疗可提高新辅助化疗+术后病理为ypN2的非小细胞肺癌患者的生存：来自SEER数据库倾向评分匹配分析

2021-12-25

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

Thorac Cancer：多中心回顾性研究评估dacomitinib（达可替尼）再挑战EGFR突变NSCLC患者的疗效

2023-03-18

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

Thorac Cancer：真实世界中晚期NSCLC患者伴有KRAS、MET、FGFR、RET、BRAF和HER2改变时一线使用免疫检查点抑制剂(ICIs)的疗效

2023-01-03

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

Thorac Cancer：伴有罕见突变的晚期或转移性NSCLC患者的真实世界数据

2022-10-14

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

J Thorac Oncol：纳武单抗+伊匹单抗治疗晚期非小细胞肺癌的长期疗效

2022-06-26

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

Thorac Cancer:淋巴结阳性(cN+)和阴性(cN0)的I期NSCLC患者术后无病生存(DFS)差异

2023-03-20

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

Thorac Cancer：晚期NSCLC奥希替尼治疗进展后化疗联合免疫治疗优于单纯化疗

2022-01-21

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

Thorac Cancer：ALK阳性是I期完全切除的肺腺癌患者无复发生存期（RFS）负性预测指标

2022-12-21

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

Thorac Cancer： EGFR-TKIs提前应用可改善不可切除的III期EGFR突变肺腺癌的预后

2022-08-22

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

J Thorac Oncol: 替雷利珠单抗（Tislelizumab）联合化疗一线治疗局部进展或转移性非鳞状非小细胞肺癌（nsq-NSCLC）的疗效和安全性(RATIONALE 304): 3期临床研究

2021-06-23

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

Thorac Cancer：伴有EGFR-T790M突变的NSCLC患者，后续奥希替尼不同顺序治疗生存对比

2022-01-31

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

J Thorac Oncol：新冠肺炎诊断的胸部恶性肿瘤患者的明确预测系统

2022-12-07

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

J Thorac Oncol: 真实世界中III期非小细胞肺癌（NSCLC）的治疗模式和临床预后：KINDLE国际多中心回顾性研究

2021-11-10

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

J Thorac Oncol：针对原发性肺癌的低剂量CT（LDCT）筛查对后续发生脑转移（BM）风险的影响。

2021-12-23

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

J Thorac Oncol：德瓦鲁单抗（durvalumab）维持治疗在EGFR和HER2突变不可切除III期NSCLC患者的作用

2021-08-06

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

J Thorac Oncol：布里加替尼治疗晚期ALK+NSCLC患者的初步结果

2022-02-14

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

J Thorac Oncol：Brigatinib（布加替尼）vs Crizotinib（克唑替尼）治疗未治ALK阳性晚期非小细胞肺癌患者的疗效：3期临床研究ALTA-1L最终分析结果

2022-06-14

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

J Thorac Oncol：Durvalumab +tremelimumab联合或不联合化疗一线治疗驱动基因阴性的转移性NSCLC患者的疗效和安全性

2022-05-08

科室
- - 订阅+
  - 更多科室
工具
服务